Nanoparticles as drug delivery systems
Abstract
Controlled drug delivery systems (DDS) have several advantages compared to the traditional forms of drugs. A drug is transported to the place of action, hence, its influence on vital tissues and undesirable side effects can be minimized. Accumulation of therapeutic compounds in the target site increases and, consequently, the required doses of drugs are lower. This modern form of therapy is especially important when there is a discrepancy between the dose or the concentration of a drug and its therapeutic results or toxic effects. Cell-specific targeting can be accomplished by attaching drugs to specially designed carriers. Various nanostructures, including liposomes, polymers, dendrimers, silicon or carbon materials, and magnetic nanoparticles, have been tested as carriers in drug delivery systems. In this review, the aforementioned nanocarriers and their connections with drugs are analyzed. Special attention is paid to the functionalization of magnetic nanoparticles as carriers in DDS. Then, the advantages and disadvantages of using magnetic nanoparticles as DDS are discussed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Different engineered nanoparticles can penetrate the blood-brain barrier and serve as efficient drug delivery systems into the brain.
“Different types of engineered nanoparticles (NPs) have been demonstrated to be able to penetrate this barrier and serve as efficient drug delivery systems (DDS) into the brain, making them a promising solution for future therapeutic development.”
Nanotechnology-based drug delivery systems using nanoparticles offer high stability, loading capacity, bioavailability, protection against enzymatic degradation, and sustained and localized release.
“These systems offer an enhanced value due to high stability, loading capacity, and bioavailability, protection against enzymatic degradation, and creation of a sustained and localized release.”
Nanoparticles provide a protective vehicle to carry and deliver therapeutic agents to the brain safely.
“Therefore, they have proven to be highly relevant in the AD context as they provide a protective vehicle to carry and deliver therapeutic agents to the brain safely [8].”
Nanoparticles are proposed as an effective alternative to cross the blood-brain barrier because their surface can be engineered to circumvent this biological barrier.
“In this way, they are proposed as an effective alternative to cross the BBB once their surface can be easily engineered to circumvent this biological barrier.”
Nanoparticles can overcome free drug limitations such as lack of selectivity and reduce the risk of adverse secondary effects by decreasing the administered drug concentration.
“Additionally, they can overcome the free drug’s limitations, like a lack of selectivity, and reduce the risk of adverse secondary effects by decreasing the drug’s administered concentration [7,8].”
Cites
Mahmoudi, M., Simchi, A., Imani, M., Shokrgozar, M. A., Milani, A. S., Häfeli, U. O., & Stroeve, P. (2010) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2009.08.044 · Cited by 294 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554 · see citing works
Stimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy
Qiao, Y., Wan, J., Zhou, L., Ma, W., Yang, Y., Luo, W., Yu, Z., & Wang, H. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1527 · Cited by 332 · see citing works
Epigenetic regulation: A new frontier for biomedical engineers
Chen, Z., Li, S., Subramaniam, S., Shyy, J. Y.-J., & Chien, S. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044720 · Cited by 163 · see citing works
Li, T., Nowell, C. J., Cipolla, D., Rades, T., & Boyd, B. J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01308 · Cited by 57 · see citing works
Recent developments in nanomaterial-based shear-sensitive drug delivery systems
Wang, Y., Pisapati, A. V., Zhang, X. F., & Cheng, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002196 · Cited by 44 · see citing works
MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40 · see citing works
Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment
Viegas, C., Pereira, D. S. M., & Fonte, P. (2022) · Materials · doi:10.3390/ma15062086 · Cited by 21 · see citing works
Silva, R., Monteiro, J., Ramalho, M. J., Andrade, S., Loureiro, J. A., & Pereira, M. C. (2026) · Pharmaceuticals · doi:10.3390/ph19050685 · Cited by 2 · see citing works
“Therefore, they have proven to be highly relevant in the AD context as they provide a protective vehicle to carry and deliver therapeutic agents to the brain safely [8].”
- Authors
- Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H.
- Affiliations
- University of Białystok (PL)
- Medical University of Białystok (PL)
- Corresponding author
- Wilczewska, Agnieszka Z.
- Car, Halina
- Venue
- Pharmacological Reports
- Published
- 2012-09
- Volume
- 64
- Issue
- 5
- Pages
- 1020-1037
- ISSN
- 1734-1140 (ISSN-L)
- OpenAlex
- W2033468145
- Cited by
- 1,445
- References
- 1
- Citations by year
- 2026: 61 · 2025: 129 · 2024: 142 · 2023: 167 · 2022: 158 · 2021: 116 · 2020: 138 · 2019: 125 · 2018: 101 · 2017: 87 · 2016: 91 · 2015: 58 · 2014: 40 · 2013: 15 · 2012: 8
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacological Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Pharmacology and Nanomedicine Research
- Keywords
- nanoparticles, drug delivery systems, controlled drug delivery, nanocarriers, liposomes, polymers, dendrimers, carbon nanomaterials, magnetic nanoparticles, cell-specific targeting, drug functionalization, targeted drug delivery
- MeSH terms
- Magnetics, Drug Delivery Systems, Nanotubes, Carbon, Dendrimers, Nanoparticles, Silica Gel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
